Quickly sort and find the exact file you need here. Send the files directly into your Shareholder Briefcase or read and right click "save target as" individual files.

Title	Date	Type	Size
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study			1.1 MB
The Bruton's Tyrosine Kinase Inhibitor PCI-32765 is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial			787.2 KB
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL			1.4 MB
2011 Annual Report			3.3 MB
September 2011 Investor Presentation	September 2011		1.1 MB
Lugano 2011 PCI-32765 Advani et al. Oral Presentation: "The Btk inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: Final results from a phase I study"			515.3 KB
Lugano 2011 PCI-32765 O'Brien et al. Oral Presentation: "The Btk Inhibitor PCI-32765 is highly active and tolerable in patients with poor-risk CLL: Interim results from a Phase Ib/II study.	Jun 15, 2011		558.8 KB
ASCO 2011 PCI-32765 Byrd et al. Oral Presentation, "Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study."	Jun 6, 2011		511.7 KB
ASCO GI PCI-27483, "Phase I/II study of PCI-27483, a coagulation factor VIIA (FVIIA) inhibitor, in advanced pancreatic cancer patients receiving treatment with gemcitabine."			356.8 KB
ASH 2010 PCI-32765 Fowler et al. Oral Presentation, "The Btk Inhibitor, PCI‐32765, Induces Durable Responses With Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From A Phase I Study"			1.0 MB
Showing 1-10 of 15 Page: 1 2  Next 10